According to reporter understanding, the internationalization of Chinese medicine release blueprint V2.0, fusion after restructuring is each business synergies, natural medicines such as ginseng and licorice the whole industry chain, medical equipment import integration services, high-end drug agents, raw materials and generic drug products are exported to overseas, such as atorvastatin calcium capsules fist products as the core, to implement specialized medical health products integrated supply chain service providers to further expand and upgrade.
In recent years, the internationalization of Chinese pharmaceutical enterprises has accelerated significantly on the whole.In particular, the flow of market factors and the adjustment of industrial structure have accelerated the depth of research, development, production and sales of Chinese and foreign enterprises.At the meeting, Xu Ming introduced the latest development of the industry: "The development of China's pharmaceutical industry in recent years has ushered in an unprecedented period. Last year, the total output value of the pharmaceutical industry reached 1.8 trillion yuan, and this year we estimate that it will exceed 2 trillion yuan, creating a new record high.Last year, the import and export volume of medical and health products, medical devices and traditional Chinese medicine reached us $81.3 billion, and this year is expected to remain stable at about US $90 billion.In other words, our foreign trade this year could also reach a new high."
China's pharmaceutical market is now bigger than Japan's.If we get to two trillion this year, we can get to the second largest pharmaceutical market in the world, excluding medical devices, bigger than Japan, and the number one is the United States.
Deep cooperation to replace low value-added exports
As we all know, for so many years, China's export of pharmaceutical products has been raw materials, medical auxiliary materials consumables and other low-value-added products as the main products.But in recent years, our exports of these low value-added products have frequently encountered a variety of difficulties and difficulties.'Since the fourth quarter of last year, we have had four consecutive quarters of negative growth in raw material exports,' Mr. Xu said, citing raw material exports as an example.According to the statistics of the national customs, our raw material export from January to September this year is only 2.7% higher than that of last year.In other words, these bulk raw materials and medical auxiliary materials have been difficult to support the internationalization process of Chinese enterprises, we must transform.
Moreover, the situation of fighting at home and abroad is very severe now, and the phenomenon of selling at low prices can be seen everywhere.Therefore, to encourage enterprises to explore more international market space, optimize product structure, obtain international high-quality resources, and cultivate our core competitiveness has become the current and future priority for a long time, which is an important field that the industry and the government must work hard in.Perhaps that means encouraging Chinese companies to deeply participate in the division of labor and cooperation between China and the West, and pushing forward the process of reengineering our value chain, Xu said.Now we have a new concept called value chain reengineering.How do you recreate it?Through deep participation in international division of labor and cooperation.
In fact, in recent years, more and more excellent enterprises such as Chinese medicine have begun to enter the international market, especially the high-end and standardized European and American markets."First of all, I feel that we have completed the first step in the process of internationalizing Chinese enterprises: internationalizing our products."Xu Ming further said that the international divided into three levels: the first level, is the level of trade, that is, we play out the products, only products do not do the market;The second level is the contract level.In recent years, many of our businesses have entered the second tier.The third level is cross-border mergers and acquisitions, listed financing.We are very pleased to see that some leading enterprises, domestic enterprises with strength, have begun to struggle at the third level.High-level internationalization is achieved.
Xu Ming said that in recent years, Chinese enterprises have also been speeding up the work of international certification. For example, our DMF files (DrugMasterFile (DMF file) of US FDA have reached 1,532, and our CEP certificates (European Pharmacopoeia adaptability certificate) have reached nearly 500.All these have created the necessary conditions for the internationalization of our Chinese enterprises.In addition, in recent years, many Chinese pharmaceutical companies have been very active in the European and American markets. At present, in the United States, we have more than 30 listed and funded pharmaceutical companies.Many more have built factories, research and development centers, marketing networks, and more.In other words, these leading enterprises began to realize the overall promotion of value chain in the process of internationalization.
Of course, the process of internationalisation has not been smooth.For example, in recent years, Chinese pharmaceutical products have been frequently subjected to anti-dumping and countervailing actions by companies from Europe, The United States and even India, and the increase has been very rapid.In addition, after entering the high-end market, it will be a challenge for Chinese enterprises to understand the local pharmaceutical administration system, insurance (reassurance) system, government procurement system, etc., and how to enter its wholesale, retail and other fields."The internationalization process of Chinese enterprises is still on the way, and we still have a long way to go."Xu Ming said.